Visual-somatosensory integration as a novel behavioral marker of amyloid pathology

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-03-07 DOI:10.1002/alz.14561

Jeannette R. Mahoney, Emmeline Ayers, Joe Verghese

{"title":"Visual-somatosensory integration as a novel behavioral marker of amyloid pathology","authors":"Jeannette R. Mahoney, Emmeline Ayers, Joe Verghese","doi":"10.1002/alz.14561","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>The ability to integrate information across sensory modalities is a vital aspect of everyday functioning and is linked to cognition. Increasing evidence suggests that Alzheimer's disease (AD) pathology manifests in sensory association areas before appearing in higher-order cognitive areas. We examined the role of visual-somatosensory integration (VSI) as a novel behavioral marker of AD-associated amyloid pathology.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>This cross-sectional study included 243 adults (77 ± 6.5 years; 52% female) who completed the VSI test and AD biomarker assays. The <i>magnitude of VSI</i> was the <i>independent variable</i> and amyloid-beta probability scores (APS; PrecivityAD<sup>TM</sup>) were the <i>dependent variable</i>. Cognitive status (normal, mild cognitive impairment, or AD) was assigned during case conferences.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Linear regression revealed an inverse association between the <i>magnitude of VSI</i> and APS (<i>β</i> = −0.16; <i>p</i> ≤ 0.01). As cognitive impairment increased from normal to dementia, the <i>magnitude of VSI</i> decreased (<i>p</i> < 0.05).</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Findings provide support for VSI impairment as a new behavioral marker of AD-associated amyloid pathology.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Here we provide support for the <i>magnitude of VSI</i> as a novel behavioral marker of AD-associated amyloid pathology given its significant association with an established, accurate, and reliable biomarker of AD pathology.</li>\n \n <li>Adults with normal cognition maintained the highest <i>magnitude of VSI</i> and brain amyloid negative scores.</li>\n \n <li>As cognitive impairment increased, the mean <i>magnitude of VSI</i> significantly decreased while amyloid probability scores (APS) increased. In fact, individuals with dementia revealed the lowest <i>magnitude of VSI</i> and the highest APS.</li>\n \n <li>Our research continues to emphasize the importance of successful multisensory integration in aging, where the establishment of future novel multisensory-based interventions aimed at preventing disability and optimizing independence could prove valuable.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 3","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14561","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.14561","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

The ability to integrate information across sensory modalities is a vital aspect of everyday functioning and is linked to cognition. Increasing evidence suggests that Alzheimer's disease (AD) pathology manifests in sensory association areas before appearing in higher-order cognitive areas. We examined the role of visual-somatosensory integration (VSI) as a novel behavioral marker of AD-associated amyloid pathology.

METHODS

This cross-sectional study included 243 adults (77 ± 6.5 years; 52% female) who completed the VSI test and AD biomarker assays. The magnitude of VSI was the independent variable and amyloid-beta probability scores (APS; PrecivityAD^TM) were the dependent variable. Cognitive status (normal, mild cognitive impairment, or AD) was assigned during case conferences.

RESULTS

Linear regression revealed an inverse association between the magnitude of VSI and APS (β = −0.16; p ≤ 0.01). As cognitive impairment increased from normal to dementia, the magnitude of VSI decreased (p < 0.05).

DISCUSSION

Findings provide support for VSI impairment as a new behavioral marker of AD-associated amyloid pathology.

Highlights

Here we provide support for the magnitude of VSI as a novel behavioral marker of AD-associated amyloid pathology given its significant association with an established, accurate, and reliable biomarker of AD pathology.
Adults with normal cognition maintained the highest magnitude of VSI and brain amyloid negative scores.
As cognitive impairment increased, the mean magnitude of VSI significantly decreased while amyloid probability scores (APS) increased. In fact, individuals with dementia revealed the lowest magnitude of VSI and the highest APS.
Our research continues to emphasize the importance of successful multisensory integration in aging, where the establishment of future novel multisensory-based interventions aimed at preventing disability and optimizing independence could prove valuable.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.